5 news items
RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040
RDHL
3 Jun 24
cancer), gastrointestinal acute radiation syndrome (GI-ARS), Sulfur Mustard exposure, COVID-19, Ebola and other viruses as part of pandemic preparedness
RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
RDHL
6 May 24
. It has a demonstrated safety and efficacy profile, and is well-suited to counter nuclear / chemical exposure and viral pandemic
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
RDHL
8 Apr 24
effect in vitro when combined with remdesivir. Management of potential Ebola virus pandemic outbreaks represents
RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price
RDHL
2 Apr 24
for pandemic preparedness, targeting multiple indications with a U.S. government collaboration for development for Acute Radiation Syndrome (ARS), a Phase 2/3
RedHill Announces New USPTO Patent Covering Talicia® Through 2034
RDHL
11 Mar 24
selective inhibitor with potential for pandemic preparedness, targeting multiple indications with a U.S. government collaboration for development
- Prev
- 1
- Next